A blood test to detect ovarian cancer in early stages

Researchers from the Universities of Adelaide and Griffith, both in Australia they developed a blood test to detect ovarian cancer in early stages as reported “Medical News Today”.

 

According to the latest data from the National Statistics Institute, Geography and Informatics (INEGI), in 2016, ovarian cancer was ranked 7.7% cause of cancer death in women 18 a 29 years.

 

Early detection of cancer can reduce mortality rate. It is estimated that 94% people whose cancer is detected in early stages have a good prognosis and good response to treatment. It is therefore important to have methods that can detect accurate manner cancer in its early stages.

 

There are currently two methods for detecting ovarian cancer in early stages plus cervical cytology (also known as the Pap test): transvaginal ultrasound and a blood test called CA-125.

 

Both tests have their limitations. Ultrasound can detect abnormal tissues in the uterus, ovaries and fallopian tubes, but can not determine if such fabrics are carcinogens. The blood test by your side, You can detect antigens in cancer, but they may also occur in other conditions such as pregnancy, endometriosis, ovarian cysts, pelvic inflammatory disease, hepatitis and cirrhosis.

 

Fortunately, researchers found a bacteria that can aid in the diagnosis of ovarian cancer in early stages. His name is Escherichia coli and it has the ability to detect cancer cells. The bacteria recognizes abnormal sugar chains present on cancer cells and released into the bloodstream.

 

The researchers designed a harmless version Escherichia coli in order to use it to detect ovarian cancer. If a blood sample taken from someone I was injected with bacteria are the aforementioned sugar chains, mean you have cancer.

In a study published in the journal “Biochemical and Biophysical Research Communications”, the effectiveness of this procedure was tested with satisfactory results. The test allowed to detect cancer 90% of patients with ovarian cancer in early stages and in the 100% those who were in advanced stages. further, no false positive was detected in samples taken from healthy people.

 

The researchers will seek to expand this study with a larger sample of blood and expect it to be soon available to the general public.

 

Sources:

Medical News Today

Biochemical and Biophysical Research Communications